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In this research topic, the primary focus is on understanding the
cellular and molecular mechanisms in the pathogenesis of differ-
ent neurodegenerative disorders. These include Alzheimer’s dis-
ease (AD), Parkinson’s disease (PD), and polyglutamine (polyQ)
expansion diseases. To date, no cure exists for these disorders
and it is paramount that research efforts continue to focus on
understanding the molecular underpinnings behind these disor-
ders. This will enable better symptom-directed therapeutics and
perhaps even curative treatments to be developed.
Throughout this topic, it becomes evident that there are com-
mon cellular pathways that are altered in these disorders, including
protein, mitochondrial, and transcriptional homeostasis. In the
case of AD, it has become widely accepted that AD is a synaptopa-
thy, meaning that there is a loss or damage of synapses. This dam-
age to synapses leads to altered neuronal circuitry. The neuron-
specific, post-synaptic protein, Arc, has gained recent attention for
its contribution in the regulation of memory consolidation. Ker-
rigan and Randall (1) discuss how alterations of Arc protein in the
brains of AD patients and animal models of AD may be a clue as to
how synaptic transmission is altered in AD, and how this cellular
pathway may be of interest for therapeutic development.
The next three reviews discuss the molecular events underlying
PD and how the normal function of specific proteins associated
with PD can help shed light on the causes of familial and sporadic
PD. Lim and Zhang (2) outline a range of studies that implicate
aberrations in mitochondrial function and protein homeostasis,
with oxidative stress as the possible link between these two. A
review from Dr. Edward A. Fon’s group complements this dis-
cussion by focusing on the structure and function of Parkin,
PINK1, and DJ-1 as they relate to PD (3). The second review
from Dr. Fon’s group digs even deeper into the role of Parkin and
PINK1 in mitophagy in neurons. They discuss the importance of
research initiatives to better define the roles of these two proteins
in mitophagy and, in particular, within the context of a neuronal
setting (4).
The next five reviews focus on polyQ expansion diseases.
Almeida et al. (5) provide a structural and functional view of trinu-
cleotide repeats and encoded homopeptide expansions, emphasiz-
ing polyQ expansions and their role in inducing the self-assembly,
aggregation, and functional alterations of the protein, leading to
neuronal toxicity and cell death. These authors focus on ataxin-3
and huntingtin (Htt), the main protein implicated in Machado–
Joseph Disease (MJD) and Huntington’s disease (HD) respectively.
Drs. Durcan and Fon, also focus on ataxin-3 and its function
as a deubiquitinating enzyme (6). These authors have recently
identified ataxin-3’s E3 ubiquitin ligase partners to be parkin
and CHIP. As MJD patients often present with PD symptoms,
the fact that parkin’s activity is regulated by ataxin-3-mediated
deubiquitination is a critical link for this phenotype. As mutant,
but not wild-type ataxin-3 promotes clearance of parkin via the
autophagy pathway, there seems to be a possibility that increased
turnover of parkin contributes to pathogenesis in MJD. More-
over, ataxin-3 also induces a reduction in CHIP levels. In light of
these findings, the authors discuss the implications for the role of
mutant ataxin-3’s effect upon Parkin and CHIP levels in under-
standing the molecular processes involved in SCA3 and perhaps
other neurodegenerative disorders.
Moumné et al. (7) discuss the role of transcriptional disruption
in HD, specifically, as it relates to the transcriptional repressor,
R element-1 silencing transcription factor (REST). REST is a
transcriptional repressor of neuronal survival factors and nor-
mally associates with wild-type Htt. However, there is an aberrant
alteration of cytoplasmic retention of the transcriptional repres-
sor REST by mutant Htt. The authors go on to describe studies
that have implicated this aberrant effect of mutant Htt on REST
function to regulate neuronal genes and how this may impact
pathogenesis in HD. Du et al. (8) focus on depression, the major
psychiatric manifestation of HD. They discuss potential mecha-
nisms of pathogenesis identified from animal models and com-
pare depression in HD patients with non-HD persons, asking
the question; Does HD-related depression differ from non-HD
persons? They also go on to discuss some molecular and cellular
mechanisms which may contribute to depression in HD.
Beitel et al. (9) discuss spinal and bulbar muscular atrophy
(SBMA), a polyQ expansion disease caused by the expansion of
a CAG tract in the androgen receptor (AR) gene. This review
summarizes all of the aspects of AR metabolism, from posttrans-
lational modifications, to protein degradation and transcriptional
function that have been implicated in SBMA pathogenesis.
Spencer et al. (10) offer a commentary on Western Pacific Amy-
otrophic lateral sclerosis (ALS) – parkinsonism-dementia complex
(PDC) that plagues the island populations of Chamorros on
Guam, Japanese in Honshu Island’s Kii Peninsula, and Papuan
New Guineans in Irian Jaya, Indonesia. It is a spectrum disorder
believed to be to be triggered by a toxin in the seed of the neuro-
toxic cycad plant. This toxin is thought to induce a prototypical
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neurodegenerative disorder linked to DNA damage and aberrant
proteogenesis.
The final review discusses how cellular surfaces modulate pro-
tein aggregation related to neurodegeneration. The interaction of
proteins with liquid/surface interfaces is a fundamental phenom-
enon with potential implications for protein-misfolding diseases.
Burke et al. (11) provide an overview of what is known about the
influence of (sub) cellular surfaces in driving protein aggregation
and/or stabilizing specific aggregate forms and how further under-
standing of such could provide new insights into toxic mechanisms
associated with these diseases.
Lastly, the methods paper by Lange et al. (12) describes a
detailed method for culturing embryonic dorsal root ganglion
neurons for Seahorse Extracellular Flux XF24 analysis. This is
a procedure used to measure the relative state of glycolytic and
aerobic metabolism in live cells, in order to assess mitochondr-
ial function. As changes in mitochondrial dynamics and function
contribute to multiple neurodegenerative diseases, this method
outlined herein is of significant interest to this topic.
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